Adverse effects of common prostate enlargement and hair growth drugs: A review

August 25, 2015

(Boston)--Twenty-five percent of men currently taking Finasteride or Dutasteride, popularly known as Proscar and Avodart, for the treatment of benign prostate enlargement (BPH), appear not to benefit from taking these medications. Those prescribed Propecia or Avodart for male pattern hair loss (known as alopecia) are also at risk for adverse events elicited by these drugs.

These findings are part of an international, collaborative review currently online in the journal Endocrine Reviews and Metabolic Disorders. Led by Abdulmaged Traish, PhD, professor of biochemistry and urology at Boston University School of Medicine (BUSM), the paper summarizes current available data and the impact of these drugs on sexual function as well as insulin resistance, depression and cognitive dysfunction.

Finasteride and Dutasteride are in the family of drugs known as 5α-reductase inhibitors (5α-RIs).They function by inhibiting the conversion of testosterone to 5α-dihydrotestosterone (5α-DHT) as well as several other critical steroid hormones. By reducing the concentration of 5α-DHT in the prostate, prostate volume decreases thus improving urinary flow.

Considerable controversy exists regarding the severity and persistence of the adverse effects of 5α-RIs, but emerging clinical evidence strongly suggests that therapy is associated with sexual adverse side effects. The package insert for Finasteride reports a libido loss and/or reduction in 10 percent of patients and erectile dysfunction in 18 percent. In some patients, these effects can remain even after stopping therapy. According to the researchers the suggestion that sexual side effects appear early in the first six months of therapy and then return to baseline is inaccurate. "The mechanism of dysfunction is likely multifactorial, related both to the direct decrease in 5α-DHT and direct influence on central and peripheral nerves," explains Traish.

In addition to sexual side effects, there has been some investigation into whether 5α-RIs can be used for prostate cancer chemo-prevention, but the researchers found the data to be inconclusive. They also believe the potential for cardiovascular side effects of therapy to warrant further investigation. "Inhibition of 5α-R activity may potentiate insulin resistance, type 2 diabetes, vascular disease and osteoporosis, but studies have not been definitive. The investigation into psychiatric side effects of 5α-RIs has been limited, but some case series describe increased depression and anxiety symptoms among patients on the medication," he adds.

The U.S. National Institutes of Health recently added post-finasteride syndrome (PFS) to its Genetic and Rare Diseases Information Center. Specific diagnostic criteria have not yet been described for the PFS spectrum. Further studies on PFS are needed to determine any relationship between dosing and severity of long-term side effects.

The authors contend that increased education and awareness of the adverse side effects of 5α-RIs is needed among clinicians and patients alike. "There needs to be a method of distinguishing who may benefit from therapy from those who will not," said Traish.

The authors also urge that further investigation into adverse side effects of 5α-RIs is needed.
-end-


Boston University Medical Center

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.